Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease and strongly correlates with the growing incidence of obesity and type II diabetes. We have developed a human-on-a-chip model composed of human hepatocytes and adipose tissue chambers capable of modeling the metabolic factors that contribute to liver disease development and progression, and evaluation of the therapeutic metformin. This model uses a serum-free, recirculating medium tailored to represent different human metabolic conditions over a 14-day period. The system validated the indirect influence of adipocyte physiology on hepatocytes that modeled important aspects of NAFLD progression, including insulin resistant biomarkers, differential adipokine signaling in different media and increased TNF-α-induced steatosis observed only in the two-tissue model. This model provides a simple but unique platform to evaluate aspects of an individual factor’s contribution to NAFLD development and mechanisms as well as evaluate preclinical drug efficacy and reassess human dosing regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
The cellular and signaling networks linking the immune system and metabolism in disease
Osborn, O., & Olefsky, J. M. (2012) · Nature Medicine · doi:10.1038/nm.2627 · Cited by 1,551
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Liver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047
Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs
Oleaga, C., Bernabini, C., Smith, A. S. T., Srinivasan, B., Jackson, M., McLamb, W., Platt, V., Bridges, R., Cai, Y., Santhanam, N., et al. (2016) · Scientific Reports · doi:10.1038/srep20030 · Cited by 442
Self-citationGene expression in human NAFLD
Greco, D., Kotronen, A., Westerbacka, J., Puig, O., Arkkila, P., Kiviluoto, T., Laitinen, S., Kolak, M., Fisher, R. M., Hamsten, A., et al. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00074.2008 · Cited by 427
Kowalski, G. M., & Bruce, C. R. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00165.2014 · Cited by 154
Cited by
In Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
Hierarchical Hydrogels with Ordered Micro-Nano Structures for Cancer-on-a-Chip Construction
Zhu, L., Shao, C., Chen, H., Chen, Z., & Zhao, Y. (2021) · Research · doi:10.34133/2021/9845679 · Cited by 41
“In particular, inspired by the physiological microstructures of hepatic sinusoid, several kinds of liver-on-a-chips have been constructed to simulate the liver microcirculation [25-27].”
BackgroundRezvani, M., Vallier, L., & Guillot, A. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.01.014 · Cited by 34
A Model of Hepatic Steatosis with Declined Viability and Function in a Liver-Organ-on-a-Chip
Wiriyakulsit, N., Keawsomnuk, P., Thongin, S., Ketsawatsomkron, P., & Muta, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-44198-0 · Cited by 29
“In most 2D models of steatosis, either of OA, PA, or OA + PA at concentrations ranging from 100 μM to 1 mM are able to induce steatosis within 24 h. Similarly, the OA + PA approach is sufficient for steatosis induction in OOC models 19,20,23,51 .”
From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
Gatzios, A., Rombaut, M., Buyl, K., De Kock, J., Rodrigues, R. M., Rogiers, V., Vanhaecke, T., & Boeckmans, J. (2022) · Biomedicines · doi:10.3390/biomedicines10010161 · Cited by 15
“A recently proposed microfluidic device consisting of primary human hepatocytes and adipocytes was able to demonstrate indirect effects of adipose tissue on hepatocytes and seems promising for use in preclinical settings [92].”
Background
Metadata
- Authors
- Slaughter, V. L., Rumsey, J. W., Boone, R., Malik, D., Cai, Y., Sriram, N. N., Long, C. J., McAleer, C. W., Lambert, S., Shuler, M. L., & Hickman, J. J.
- Venue
- Scientific Reports
- Published
- 2021-06-23
- Volume
- 11
- Issue
- 1
- Pages
- 13159-13159
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W3175942311
- Cited by
- 65
- References
- 11
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation. https://app.cochat.ai/papers/10.1038/s41598-021-92264-2
- The paper
- Slaughter, V. L., Rumsey, J. W., Boone, R., Malik, D., Cai, Y., Sriram, N. N., Long, C. J., McAleer, C. W., Lambert, S., Shuler, M. L., & Hickman, J. J. (2021). Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation. Scientific Reports. https://doi.org/10.1038/s41598-021-92264-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.